2025 Q4 -tulosraportti

UUTTA

6 päivää sitten

7,95 DKK/osake

Irtoamispäivä 27.3.

3,70%Tuotto/v

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

3 009 039

Myynti

Määrä

2 927 154

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
18.13.44	100 000	NRD	NRD
18.08.00	86	-	-
18.08.00	514	-	-
18.03.33	50	-	-
18.03.28	50	-	-

Ylin

312

VWAP

306,76

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

VWAP

306,76

Ylin

312

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 6.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 5.2.
Ylimääräinen yhtiökokous 2025 14.11.2025
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 7.8.2025
2025 Q1 -tulosraportti 8.5.2025

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Xpages
1 t sitten
·
Xpages
1 t sitten
·
What do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
SvanenDK
57 min sitten
·
SvanenDK
57 min sitten
·
And why shouldn't he be allowed to?🤷‍♂️ you surely know janteloven
TaqiaDk
2 t sitten
·
TaqiaDk
2 t sitten
·
In the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”
SvanenDK
56 min sitten
·
SvanenDK
56 min sitten
·
There are no figures out before Friday.
slowincrease
48 min sitten
·
slowincrease
48 min sitten
·
Obviously, that's what it is.
rune66
2 t sitten
·
rune66
2 t sitten
·
Agree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
SvanenDK
54 min sitten
·
SvanenDK
54 min sitten
·
Several deaths have occurred with compounded products, Hims has a lot of unpleasant cases
Boss786
2 t sitten
Boss786
2 t sitten
The gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
Jan78
28 min sitten
·
Jan78
28 min sitten
·
A good post👍🏻
Pomfritt
3 t sitten
·
Pomfritt
3 t sitten
·
Our beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Jan78
26 min sitten
·
Jan78
26 min sitten
·
Pomfritt: What is it you don't understand about the sale? This is the second employee selling shares this week. They have a limited time window to sell, and it is often sold at this time to pay taxes. Money one doesn't have in a bank account.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

UUTTA

6 päivää sitten

7,95 DKK/osake

Irtoamispäivä 27.3.

3,70%Tuotto/v

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Xpages
1 t sitten
·
Xpages
1 t sitten
·
What do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
SvanenDK
57 min sitten
·
SvanenDK
57 min sitten
·
And why shouldn't he be allowed to?🤷‍♂️ you surely know janteloven
TaqiaDk
2 t sitten
·
TaqiaDk
2 t sitten
·
In the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”
SvanenDK
56 min sitten
·
SvanenDK
56 min sitten
·
There are no figures out before Friday.
slowincrease
48 min sitten
·
slowincrease
48 min sitten
·
Obviously, that's what it is.
rune66
2 t sitten
·
rune66
2 t sitten
·
Agree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
SvanenDK
54 min sitten
·
SvanenDK
54 min sitten
·
Several deaths have occurred with compounded products, Hims has a lot of unpleasant cases
Boss786
2 t sitten
Boss786
2 t sitten
The gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
Jan78
28 min sitten
·
Jan78
28 min sitten
·
A good post👍🏻
Pomfritt
3 t sitten
·
Pomfritt
3 t sitten
·
Our beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Jan78
26 min sitten
·
Jan78
26 min sitten
·
Pomfritt: What is it you don't understand about the sale? This is the second employee selling shares this week. They have a limited time window to sell, and it is often sold at this time to pay taxes. Money one doesn't have in a bank account.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

3 009 039

Myynti

Määrä

2 927 154

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
18.13.44	100 000	NRD	NRD
18.08.00	86	-	-
18.08.00	514	-	-
18.03.33	50	-	-
18.03.28	50	-	-

Ylin

312

VWAP

306,76

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

VWAP

306,76

Ylin

312

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 6.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 5.2.
Ylimääräinen yhtiökokous 2025 14.11.2025
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 7.8.2025
2025 Q1 -tulosraportti 8.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

UUTTA

6 päivää sitten

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 6.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 5.2.
Ylimääräinen yhtiökokous 2025 14.11.2025
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 7.8.2025
2025 Q1 -tulosraportti 8.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

7,95 DKK/osake

Irtoamispäivä 27.3.

3,70%Tuotto/v

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Xpages
1 t sitten
·
Xpages
1 t sitten
·
What do you gentlemen think about the CFO having sold for 8mill - surely not exactly a sign that he believes in it / progress for Novo ? (Well aware that the man is subject to special rules regarding buying/selling)
SvanenDK
57 min sitten
·
SvanenDK
57 min sitten
·
And why shouldn't he be allowed to?🤷‍♂️ you surely know janteloven
TaqiaDk
2 t sitten
·
TaqiaDk
2 t sitten
·
In the annual report, the Wegovy pill was at 170.000, and now 1 week later with the new prescription figures +the unknown ones, they have gained 76.000 new ones💪🏻 “Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.”
SvanenDK
56 min sitten
·
SvanenDK
56 min sitten
·
There are no figures out before Friday.
slowincrease
48 min sitten
·
slowincrease
48 min sitten
·
Obviously, that's what it is.
rune66
2 t sitten
·
rune66
2 t sitten
·
Agree that it's a good interview on Fox, and really good that he steps up and makes sure to get into the media in the USA. I don't quite understand the background for Novo continuing to highlight patient safety as a problem with compound products. Of the 1.,5 million people who take compounds, how many have received an impure product that has led to complications? If there was a problem, wouldn't we have heard about it from sick compourd users?
SvanenDK
54 min sitten
·
SvanenDK
54 min sitten
·
Several deaths have occurred with compounded products, Hims has a lot of unpleasant cases
Boss786
2 t sitten
Boss786
2 t sitten
The gap is closing $NVO $LLY The latest weekly prescription data (New-to-Brand or NBRx) for the week ending Jan 30 is out, and it confirms the thesis we have seen since the start of the year: momentum has shifted. For the last six months, the bear case on Novo Nordisk was simple: "Lilly is winning 70% of the new patients." That argument no longer holds. The "starter dose" dead heat: - The most important leading indicator for future market share is "starter doses" (new patients entering therapy). • Zepbound starters: 42’164 (+0.5% WoW) • Wegovy starters: 41’867 (+2% WoW) The gap is now less than 300 prescriptions. We are effectively at parity. Zepbound’s share of the starter market has gone down to 50.2%, meaning the market is now a true 50/50 duopoly again, rather than a Lilly monopoly. The Oral catalyst: The driver of this resurgence is clear. 21’153 of those new Wegovy starters were for the Oral pill. Nearly half of all new patients entering the Wegovy ecosystem are bypassing the needle entirely. This validates the "frictionless" thesis: at $149, the pill is unlocking a demographic that Zepbound even with vials simply is not reaching. No cannibalization: Importantly, the data shows that the pill is additive. The high proportion of oral starters combined with the stability of the overall franchise suggests that existing pen users are staying put, while the pill is adding up the new to therapy patients. Novo did not just stop the bleeding, they have successfully deployed a new tool that has neutralized Lilly’s momentum in less than 30 days. Strong funnel momentum for Novo.
Jan78
28 min sitten
·
Jan78
28 min sitten
·
A good post👍🏻
Pomfritt
3 t sitten
·
Pomfritt
3 t sitten
·
Our beloved CFO has sold shares for over 8 million. I will probably never be completely fond of that man. He is also a disaster when there are earnings presentations. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen 2 Reason for the notification a) Position/status Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s) Volume(s) DKK 315.60 26,246 d) Aggregated information Aggregated volume Price
Jan78
26 min sitten
·
Jan78
26 min sitten
·
Pomfritt: What is it you don't understand about the sale? This is the second employee selling shares this week. They have a limited time window to sell, and it is often sold at this time to pay taxes. Money one doesn't have in a bank account.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

3 009 039

Myynti

Määrä

2 927 154

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
18.13.44	100 000	NRD	NRD
18.08.00	86	-	-
18.08.00	514	-	-
18.03.33	50	-	-
18.03.28	50	-	-

Ylin

312

VWAP

306,76

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

VWAP

306,76

Ylin

312

Alin

302,85

VaihtoMäärä

2 122,9 6 921 069

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä